Aspiriant LLC Makes New $661,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Aspiriant LLC acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,693 shares of the company's stock, valued at approximately $661,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEM. Victory Capital Management Inc. acquired a new position in shares of Tempus AI in the 4th quarter valued at about $216,000. Wells Fargo & Company MN increased its stake in shares of Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after acquiring an additional 278 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in shares of Tempus AI in the first quarter worth $535,000. ProShare Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter worth $244,000. Finally, Avanza Fonder AB increased its position in Tempus AI by 15.8% in the 1st quarter. Avanza Fonder AB now owns 41,005 shares of the company's stock worth $2,047,000 after purchasing an additional 5,591 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Insiders Place Their Bets

In other Tempus AI news, Director Theodore Leonsis sold 205,847 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $67.66, for a total value of $13,927,608.02. Following the transaction, the director now directly owns 15,511 shares of the company's stock, valued at $1,049,474.26. This represents a 92.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 3,000 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the transaction, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. This represents a 10.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 308,580 shares of company stock valued at $20,156,721 in the last 90 days. 27.60% of the stock is currently owned by insiders.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $70.11 on Wednesday. The firm's 50 day simple moving average is $57.12 and its 200 day simple moving average is $52.50. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.71 and a quick ratio of 1.56. The company has a market capitalization of $12.14 billion and a price-to-earnings ratio of -8.99. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The business had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. The company's revenue was up 75.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Analyst Ratings Changes

TEM has been the topic of a number of research reports. Needham & Company LLC restated a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a report on Wednesday, May 7th. Piper Sandler increased their target price on shares of Tempus AI from $55.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, May 15th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Bank of America increased their target price on shares of Tempus AI from $48.00 to $68.00 and gave the stock a "neutral" rating in a research report on Tuesday, May 20th. Finally, William Blair reissued a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $63.42.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.